| Neoepitopes as cancer immunotherapy targets: key challenges and opportunities CA Brennick, MM George, WL Corwin, PK Srivastava, H Ebrahimi-Nik Immunotherapy 9 (4), 361-371, 2017 | 79 | 2017 |
| In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer J Dubrot, PP Du, SK Lane-Reticker, EA Kessler, AJ Muscato, A Mehta, ... Nature Immunology 23 (10), 1495-1506, 2022 | 75 | 2022 |
| Mass spectrometry–driven exploration reveals nuances of neoepitope-driven tumor rejection H Ebrahimi-Nik, J Michaux, WL Corwin, GLJ Keller, T Shcheglova, ... JCI insight 4 (14), 2019 | 60 | 2019 |
| Bacterial ghost of avian pathogenic E. coli (APEC) serotype O78:K80 as a homologous vaccine against avian colibacillosis H Ebrahimi-Nik, MR Bassami, M Mohri, M Rad, MI Khan PLoS One 13 (3), e0194888, 2018 | 43 | 2018 |
| The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity CK Baumgartner, H Ebrahimi-Nik, A Iracheta-Vellve, KM Hamel, ... Nature 622 (7984), 850-862, 2023 | 29 | 2023 |
| Tumor Control Index as a new tool to assess tumor growth in experimental animals WL Corwin, H Ebrahimi-Nik, SM Floyd, P Tavousi, II Mandoiu, ... Journal of immunological methods 445, 71-76, 2017 | 28 | 2017 |
| CD11c+ MHCIIlo GM-CSF-bone marrow-derived dendritic cells act as antigen donor cells and as antigen presenting cells in neoepitope-elicited tumor immunity … H Ebrahimi-Nik, WL Corwin, T Shcheglova, A Das Mohapatra, II Mandoiu, ... Cancer Immunology, Immunotherapy 67, 1449-1459, 2018 | 22 | 2018 |
| Reversion analysis reveals the in vivo immunogenicity of a poorly MHC I-binding cancer neoepitope H Ebrahimi-Nik, M Moussa, RP Englander, S Singhaviranon, J Michaux, ... Nature Communications 12 (1), 6423, 2021 | 20 | 2021 |
| Strong antitumor activity of bevacizumab and aflibercept in neuroendocrine carcinomas: In-depth preclinical study M Rodríguez-Remírez, L del Puerto-Nevado, MJ Fernández Aceñero, ... Neuroendocrinology 110 (1-2), 50-62, 2020 | 7 | 2020 |
| Targeting the immune checkpoint PTPN2 with ABBV-CLS-484 inflames the tumor microenvironment and unleashes potent CD8+ T cell immunity A Iracheta-Vellve, H Ebrahimi-Nik, TR Davis, KE Olander, SY Kim, ... Cancer Research 82 (12_Supplement), 606-606, 2022 | 4 | 2022 |
| 1365 An active site PTPN2/N1 small molecule inhibitor promotes anti-tumor efficacy by sensitizing tumor cells to inflammatory signals and enhancing immune cell activity K McGuire, C Baumgartner, C Backus, R Mathew, K Klinge, J Klahn, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | 1 | 2022 |
| Bacterial ghost” as a novel vaccine designing method HE Nik Retrieved September 12, 2019, 2015 | 1 | 2015 |
| In vitro studies to develop a bacterial ghost of avian pathogenic E. coli (APEC) serotype 078 as a non-viable oral and parentral vaccine against avian colibacilosis H Ebrahimi Nik, MR Bassami, M Mohri, M Rad, BN Fasaei 4th international veterinary poultry congress, 2014 | 1 | 2014 |
| 1403-A PTPN2/N1 inhibitor ABBV-CLS-484 unleashes potent anti-tumor immunity H Ebrahimi-Nik, CK Baumgartner, A Iracheta-Vellve, KM Hamel, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 2), 2023 | | 2023 |
| 999 The PTPN2/N1 small molecule inhibitor ABBV-CLS-484 promotes NK cell activity driving primary tumor regression and preventing metastasis C Patel, KA McGuire, H Ebrahimi-Nik, M Sun, Y Liu, K Klinge, J Aguado, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| Abstract A41: Small molecule inhibition of PTPN2/1 inflames the tumour microenvironment and unleashes potent CD8+ T cell immunity H Ebrahimi-Nik, A Iracheta-Vellve, KE Olander, TRG Davis, SY Kim, ... Cancer Immunology Research 10 (12_Supplement), A41-A41, 2022 | | 2022 |
| CRISPR-guided reversion reveals the immunogenicity of a “non-MHC binding” cancer neoepitope in vivo H Ebrahimi-Nik, M Moussa, R Englander, S Singhaviranon, J Michaux, ... | | 2020 |
| Dendritic Cells as a Novel Delivery System for Immunotherapy PK Srivastava, H Ebrahimi-Nik US Patent App. 16/612,481, 2020 | | 2020 |
| Mass spectroscopy-defined neoepitopes are a rich source of tumor rejection-mediating neoepitopes in a mouse sarcoma H Ebrahimi-Nik, T Shcheglova, J Michaux, HS Pak, E Sherafat, S Al Seesi, ... The Journal of Immunology 202 (1_Supplement), 70.13-70.13, 2019 | | 2019 |
| Characterization of a Single Nucleotide Variant of Ccdc85c as a Tumor Rejection-Mediating Neoepitope of Meth A Fibrosarcoma H Ebrahimi-Nik, WL Corwin, II Mandoiu, PK Srivastava The Journal of Immunology 200 (1_Supplement), 181.21-181.21, 2018 | | 2018 |
Pramod K Srivastava PhD MDUniversity of Connecticut School of MedicineVerified email at uchc.edu
